| 1169419 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Immunology – SARS-CoV-2 (Ab) (416)
[Virusimmunologie - SARS-CoV-2 (Ak) (416)]
Virus Immunology – SARS-CoV-2 (Ab) (416)
[Virusimmunologie - SARS-CoV-2 (Ak) (416)]
|
2025-11-20 |
|
|
| PT name |
(Virus Immunology – SARS-CoV-2 (Ab) (416)) |
| Scheme name in national language |
(Virusimmunologie - SARS-CoV-2 (Ak) (416)) |
| Tested property |
(Anti-SARS-CoV-2 total (without differentiation of IgG, IgA and IgM)) (Anti-SARS-CoV-2 IgG) (Anti-SARS-CoV-2 IgG avidity (not certified)) (Anti-SARS-CoV-2 IgA (not certified)) (Anti-SARS-CoV-2 IgM (not certified)) |
|
| 1163304 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – Respiratory Virus Panel 1 for Multiplex Tests (431)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 1 für Multiplex Teste (431)]
Virus Genome Detection – Respiratory Virus Panel 1 for Multiplex Tests (431)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 1 für Multiplex Teste (431)]
|
2024-04-16 |
|
|
| Tested property |
(incl. avian influenza A viruses, parecho, parainfluenza, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated), respectively) |
|
| 1163321 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – Respiratory Virus Panel 2 for Multiplex Tests (432)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 2 für Multiplex Teste (432)]
Virus Genome Detection – Respiratory Virus Panel 2 for Multiplex Tests (432)
[Virusgenom-Nachweis - Respiratorisches Virus-Panel 2 für Multiplex Teste (432)]
|
2024-04-16 |
|
|
| Tested property |
(influenza A and B viruses incl. avian influenza A viruses, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated)) |
|
| 1163338 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – SARS-CoV-2 (409)
[Virusgenom-Nachweis - SARS-CoV-2 (409)]
Virus Genome Detection – SARS-CoV-2 (409)
[Virusgenom-Nachweis - SARS-CoV-2 (409)]
|
2025-11-20 |
|
|
| PT name |
(Virus Genome Detection – SARS-CoV-2 (409)) |
| Remarks |
(The sample set contains defined samples with SARS-CoV-2 (full virus, inactivated).
The) |
| Scheme name in national language |
(Virusgenom-Nachweis - SARS-CoV-2 (409)) |
| Tested property |
(Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV-2) |
|
| 1163345 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – SARS-CoV-2 sequence analysis (417)
[Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)]
Virus Genome Detection – SARS-CoV-2 sequence analysis (417)
[Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)]
|
2025-11-20 |
|
|
| PT name |
(Virus Genome Detection – SARS-CoV-2 sequence analysis (417)) |
| Scheme name in national language |
(Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)) |
| Tested property |
(Differentiation of SARS-CoV-2 variants with clinical relevance using whole genome sequencing) |
|
| 1160040 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Antigen Detection – SARS-CoV-2 (Ag) (410)
[Virusantigen-Nachweis - SARS-CoV-2 (Ag) (410)]
Virus Antigen Detection – SARS-CoV-2 (Ag) (410)
[Virusantigen-Nachweis - SARS-CoV-2 (Ag) (410)]
|
2025-11-20 |
|
|
| PT name |
(Virus Antigen Detection – SARS-CoV-2 (Ag) (410)) |
| Remarks |
(The sample set contains defined samples with antigen from SARS-CoV-2 (inactivated).
For POCT) (samples are suitable for rapid tests and automated immunoassays for the detection of SARS-CoV-2) |
| Scheme name in national language |
(Virusantigen-Nachweis - SARS-CoV-2 (Ag) (410)) |
| Tested property |
(SARS-CoV-2 antigen) |
|
| 134427 |
United Kingdom |
LGC AXIO Proficiency Testing
LGC AXIO Proficiency Testing
|
Water Microbiology Scheme - (QWAS)
Water Microbiology Scheme - (QWAS)
|
2021-03-01 |
|
|
| Tested property |
(SARS-CoV-2) (Detection of SARS-CoV-2) (Optional quantification of SARS-CoV-2 (Trial)) |
| Testing method |
(2 x 1.5 ml vial (A & B) of non-infectious, SARS-CoV-2 virus (whole genome) 1 x >100ml sterile water diluent 1 x >20g sterile sludge matrix) |
|
| 302644 |
United Kingdom |
LGC AXIO Proficiency Testing
LGC AXIO Proficiency Testing
|
Environmental Hygiene Monitoring Scheme- HYGIENE
Environmental Hygiene Monitoring Scheme- HYGIENE
|
2021-09-06 |
|
|
| Test item |
(Surface testing (swab rinsate) for SARS-CoV-2 molecular) |
| Tested property |
(SARS-CoV-2) |
|
| 1083473 |
Brazil |
METROCERT
METROCERT
|
P-021 - Proficiency testing program for Specific Absorption Rate (SAR) testing on a cellular mobile phone
[P-021 - Programa de ensaio de proficiência para ensaio de Taxa de Absorção Específica (SAR) em telefone móvel celular]
P-021 - Proficiency testing program for Specific Absorption Rate (SAR) testing on a cellular mobile phone
[P-021 - Programa de ensaio de proficiência para ensaio de Taxa de Absorção Específica (SAR) em telefone móvel celular]
|
2023-10-19 |
|
|
| PT name |
(P-021 - Proficiency testing program for Specific Absorption Rate (SAR) testing on a cellular mobile phone) |
| Scheme name in national language |
(P-021 - Programa de ensaio de proficiência para ensaio de Taxa de Absorção Específica (SAR) em telefone móvel celular) |
| Tested property |
(Specific Absorption Rate (SAR)) |
|
| 706310 |
Portugal |
Programa Nacional de Avaliação Externa da Qualidade (PNAEQ) INSA DEP UAEQ
Programa Nacional de Avaliação Externa da Qualidade (PNAEQ) INSA DEP UAEQ
|
SARS-CoV-2, molecular detection
[SARS-CoV-2, molecular detection]
SARS-CoV-2, molecular detection
[SARS-CoV-2, molecular detection]
|
2024-03-13 |
|
|
| PT name |
(SARS-CoV-2, molecular detection) |
| Scheme name in national language |
(SARS-CoV-2, molecular detection) |
| Tested property |
(SARS-CoV-2 virus) |
|
| 837442 |
Brazil |
PROGRAMA NACIONAL DE CONTROLE DE QUALIDADE
PROGRAMA NACIONAL DE CONTROLE DE QUALIDADE
|
COVID-19 (SARS-CoV2) IMUNOCROMATOGRAFIA
[COVID-19 (SARS-CoV2) IMUNOCROMATOGRAFIA]
COVID-19 (SARS-CoV2) IMUNOCROMATOGRAFIA
[COVID-19 (SARS-CoV2) IMUNOCROMATOGRAFIA]
|
2022-05-30 |
|
|
| PT name |
(COVID-19 (SARS-CoV2) IMUNOCROMATOGRAFIA) |
| Scheme name in national language |
(COVID-19 (SARS-CoV2) IMUNOCROMATOGRAFIA) |
|
| 143957 |
United Kingdom |
Public Health England
Public Health England
|
Food and Environmental Proficiency Testing Unit (FEPTU)
Food and Environmental Proficiency Testing Unit (FEPTU)
|
2025-04-15 |
|
|
| Tested property |
(SARS-CoV-2) |
|
| 807218 |
Brazil |
QLM Inovações Tecnológicas
QLM Inovações Tecnológicas
|
Interlaboratorial Program Test Mobile Phone
[Comparação Interlaboratorial em Ensaio em telefone celular]
Interlaboratorial Program Test Mobile Phone
[Comparação Interlaboratorial em Ensaio em telefone celular]
|
2024-10-18 |
|
|
|
| 1271562 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
Virus serology: SARS-CoV-2
[Vírus szerológia: SARS-CoV-2]
Virus serology: SARS-CoV-2
[Vírus szerológia: SARS-CoV-2]
|
2026-03-19 |
|
|
| PT name |
(Virus serology: SARS-CoV-2) |
| Remarks |
(The content of the scheme: SARS-CoV-2 antibody (IgG-, IgG-S, IgG-N, IgM, IgA, total antibody) |
| Scheme name in national language |
(Vírus szerológia: SARS-CoV-2) |
| Tested property |
(Anti-SARS-CoV-2 total (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG-S (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG-N (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgM (OD, S/CO, quantitative, evaluation)) |
|
| 1271426 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
Virus nucleic acid determination: SARS-CoV-2
[Vírus nukleinsav meghatározás: SARS-CoV-2]
Virus nucleic acid determination: SARS-CoV-2
[Vírus nukleinsav meghatározás: SARS-CoV-2]
|
2026-03-19 |
|
|
| PT name |
(Virus nucleic acid determination: SARS-CoV-2) |
| Remarks |
(amplification techniques (NAT) for qualitative determination of SARS-CoV-2 virus. Qualitative results are) |
| Scheme name in national language |
(Vírus nukleinsav meghatározás: SARS-CoV-2) |
|
| 1271523 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
POCT: SARS-CoV-2
[POCT: SARS-CoV-2]
POCT: SARS-CoV-2
[POCT: SARS-CoV-2]
|
2026-03-19 |
|
|
| PT name |
(POCT: SARS-CoV-2) |
| Remarks |
(The content of the scheme: SARS-CoV-2 antibody (IgG, IgM, total antibody) and antigen determination) |
| Scheme name in national language |
(POCT: SARS-CoV-2) |
| Tested property |
(Anti-SARS-CoV-2 total qualitative) (Anti-SARS-CoV-2 - IgG qualitative) (Anti-SARS-CoV-2 - IgM qualitative) (SARS-CoV-2 Antigen qualitative) (SARS-CoV-2 interpretation) |
|
| 789737 |
Australia |
RCPAQAP
RCPAQAP
|
Molecular Coronavirus SARS-CoV-2
Molecular Coronavirus SARS-CoV-2
|
2020-10-28 |
|
|
| PT name |
(Molecular Coronavirus SARS-CoV-2) |
| Tested property |
(Coronavirus SARS-CoV2) |
|
| 789879 |
Australia |
RCPAQAP
RCPAQAP
|
Molecular Respiratory Pathogens
Molecular Respiratory Pathogens
|
2020-10-28 |
|
|
| Tested property |
(Coronavirus (OC43, NL63, SARS-CoV-2)) |
|
| 794057 |
Australia |
RCPAQAP
RCPAQAP
|
PHLN: SARS-CoV-2 and other coronaviruses
PHLN: SARS-CoV-2 and other coronaviruses
|
2020-10-23 |
|
|
| PT name |
(PHLN: SARS-CoV-2 and other coronaviruses) |
| Remarks |
(Department of Health funded COVID-19 program. Three rounds of this module were offered in 2020 in) (response to the COVID-19 pandemic with plans for another in 2021. This module is suitable for all) (laboratory testing platforms that are utilised in the whole genome sequencing of SARS-CoV-2.
Available) (free of charge to Australian public health laboratories that require the capability to test for SARS-CoV-2.) |
| Tested property |
(Diluted SARS-CoV-2 (inactivated)) (Diluted SARS-CoV-2 (inactivated)) |
|
| 790376 |
Australia |
RCPAQAP
RCPAQAP
|
PoCT: COVID-19 serology (IgG/IgM)
PoCT: COVID-19 serology (IgG/IgM)
|
2020-10-26 |
|
|
| PT name |
(PoCT: COVID-19 serology (IgG/IgM)) |
| Tested property |
(COVID-19 Serology) |
|
